Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 46

Sort by

Sort Order Select

Journal Articles

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent

Sarvarinder Gill, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 7032.

https://doi.org/10.1182/blood-2025-7032

Published: 2025

Journal Articles

Trials in progress: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

Catherine Lai, Kimberley Doucette, Susan Mckay, Ashlena Livingston, Jed Osei, Ella Rutanen, Jacqueline Galdos, Kristina Krstanoska, Nicole Swanson, Kerrie Bouker, James McCloskey

Blood (2025) 146 (Supplement 1): 8255.

https://doi.org/10.1182/blood-2025-8255

Published: 2025

Journal Articles

AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia

Sarvarinder Gill, Maher Albitar, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2025-1731

Published: 2025

Journal Articles

A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Guillermo Garcia-Manero, Uma Borate, Andrew Brunner, Bonnie Kiner-Strachan, Bart Scott, Yazan Madanat, Michael Savona, Elizabeth Griffiths, Aram Oganesian, Yuri Sano, Lixia Zhu, Gareth Tomlinson, Danna Chan, Harold Keer, James McCloskey

Blood (2025) 146 (Supplement 1): 491.

https://doi.org/10.1182/blood-2025-491

Published: 2025

Journal Articles

Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).

Guillermo Garcia-Manero, Yazan Madanat, Mikkael Sekeres, Hetty Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary Schiller, Frank Hsu, Toufigh Gordi, Lisa Rojkjaer, Lewis R Silverman

Blood (2025) 146 (Supplement 1): 489.

https://doi.org/10.1182/blood-2025-489

Published: 2025

Journal Articles

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Blood (2025) 146 (Supplement 1): 482.

https://doi.org/10.1182/blood-2025-482

Published: 2025

Journal Articles

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Blood (2025) 146 (Supplement 1): 764.

https://doi.org/10.1182/blood-2025-764

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Journal Articles

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

Maher Albitar, Hong Zhang, Gustavo Rivero, David Swoboda, Sally Agersborg, Adam Albitar, Ahmad Charifa, Andrew Ip, Andre Goy, Andrew Pecora, David Siegel, Kelly West Fitzpatrick, Katherine Linder, Jamie Koprivnikar, James McCloskey

Blood (2025) 146 (Supplement 1): 5251.

https://doi.org/10.1182/blood-2025-5251

Published: 2025

Journal Articles

Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors

Blood (2025) 146 (Supplement 1): 3471.

https://doi.org/10.1182/blood-2025-3471

Published: 2025

Journal Articles

Bone marrow microenvironment overlap between vexas and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence

Maher Albitar, Sally Agersborg, Hong Zhang, Adam Albitar, Ahmad Charifa, Andrew Pecora, David Siegel, Andre Goy, Jamie Koprivnikar, James McCloskey, Katherine Linder

Blood (2025) 146 (Supplement 1): 5611.

https://doi.org/10.1182/blood-2025-5611

Published: 2025

Journal Articles

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Blood (2025) 146 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2025-2018

Published: 2025

Journal Articles

Molecular correlates of response and survival with venetoclax plus hypomethylating agent in treatment-Naïve high-risk myelodysplastic syndrome

Sarvarinder Gill, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, James McCloskey

Blood (2025) 146 (Supplement 1): 7386.

https://doi.org/10.1182/blood-2025-7386

Published: 2025

Journal Articles

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Guillermo Garcia-Manero, Yazan F Madanat, Mikkael A. Sekeres, Hetty E. Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary J. Schiller, Lucy Yan, Toufigh Gordi, Lisa Rojkjaer, Lewis R. Silverman

Blood (2024) 144 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2024-206096

Published: 2024

Journal Articles

Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience

Sarvarinder Kaur Gill, Geeny Lee, Joelle Rubin, Shuqi Wang, Jamie Koprivnikar, Katherine Linder, James McCloskey

Blood (2024) 144 (Supplement 1): 1448.

https://doi.org/10.1182/blood-2024-210149

Published: 2024

Journal Articles

Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Ajibade Ashaye, Ling Shi, Ibrahim Aldoss, Pau Montesinos, Pankit Vachhani, Cristina Papayannidis, Jessica T. Leonard, Maria R. Baer, Josep-Maria Ribera, James McCloskey, JianXiang Wang, Sujun Gao, Deepali Rane, Shien Guo

Blood (2024) 144 (Supplement 1): 2825.

https://doi.org/10.1182/blood-2024-208755

Published: 2024

Journal Articles

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Blood (2024) 144 (Supplement 1): 2821.

https://doi.org/10.1182/blood-2024-208504

Published: 2024

Journal Articles

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)

Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Andrew M. Brunner, Amer M. Zeidan, Elie Traer, Yazan F. Madanat, Janelle Meyer, Harry Erba, Praneeth Baratam, Uma Borate, Yuri Sano, Aram Oganesian, Lixia Zhu, Harold N. Keer, Michael R. Savona

Blood (2024) 144 (Supplement 1): 662.

https://doi.org/10.1182/blood-2024-203569

Published: 2024

Journal Articles

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

Samuel Urrutia, Koji Sasaki, Alex Bataller, Hagop M. Kantarjian, Guillermo Montalban-Bravo, James McCloskey, Elizabeth A. Griffiths, Karen Yee, Amer M. Zeidan, Michael R. Savona, Aram Oganesian, Yuri Sano, Harold N. Keer, Guillermo Garcia-Manero

Blood (2024) 144 (Supplement 1): 661.

https://doi.org/10.1182/blood-2024-193274

Published: 2024

Journal Articles

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Blood (2024) 144 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2024-207634

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

IDH1 mutation predicts response and survival in treatment-naïve Acute Myeloid Leukemia patients receiving with venetoclax with a hypomethylating agent

Trials in progress: Phase IB/II of CPX-351 as maintenance therapy in AML patients ineligible for bone marrow transplantation

AI-derived prediction of response and relapse to venetoclax plus hypomethylating agent based therapy in Acute Myeloid Leukemia

A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia

Safety and efficacy results from A phase 1b study of R289, a dual irak 1/4 inhibitor, in patients with Relapsed/Refractory (R/R) lower risk myelodysplastic syndrome (LR-MDS).

Preliminary data from the Phase I/II study of nuvisertib, an oral investigational selective PIM1 inhibitor, in combination with momelotinib showed clinical responses in patients with relapsed/refractory myelofibrosis

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation-negative leukemia

Developing artificial intelligence-based transcriptomic signature for selecting patients with HOXA-MEIS1 pathway abnormalities for the treatment with menin inhibitors

Bone marrow microenvironment overlap between vexas and myelodysplastic syndrome demonstrated by targeted transcriptomic and artificial intelligence

Nuvisertib, an oral investigational selective PIM1 kinase inhibitor, showed clinical responses strongly correlating with cytokine modulation in patients with relapsed/refractory myelofibrosis in the ongoing global phase I/II study

Molecular correlates of response and survival with venetoclax plus hypomethylating agent in treatment-Naïve high-risk myelodysplastic syndrome

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Augmented Hyper-CVAD (AHCVAD), a Pediatric Inspired Regimen for Adults Younger Than 50 Years of Age with Acute Lymphoblastic Leukemia (ALL), Yields High Rates of MRD Negativity, Favorable 3-Year Overall Survival Regardless of Allogeneic Stem Cell Transplant (ASCT): A Single Center Experience

Quality-Adjusted Time without Symptoms of Disease or Toxicity (Q-TWiST) of Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Ponatinib Monotherapy after Combination with Chemotherapy in Patients with Newly Diagnosed Ph+ ALL: Post Hoc Subgroup Analysis of the Phase 3 Phallcon Study

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)

Oral Decitabine/Cedazuridine in Patients with MDS and TP53 Mutations: A Propensity Score Matching Analysis from the Phase II and III Trials

5-Year Follow-up of the Phase 2 Optic Study in Patients with Chronic-Phase Chronic Myeloid Leukemia: Efficacy, Safety, and First End-of-Treatment Mutational Results

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only